The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia BEAM-102 for the treatment of. Read Lessīeam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. Vol.) 166,416 Days Range 9.15 - 9.86 52-Week Range 9.15 - 39.39 Dividend & Yield N/A (N/A) BEEM Stock Predictions, Articles, and Beam Global News From InvestorPlace From the. The company was incorporated in 2017 and is based in Cambridge, Massachusetts. According to our technical indicators, the current sentiment is while the Fear & Greed Index is showing Fear. shares will drop by -4.50and reach 12.85 per share by May 25, 2022. According to our current BEEM stock forecast, the value of Envision Solar International, Inc. and collaboration and license agreement with Verve Therapeutics, Inc. Once we get enough data we will add BEEMstock forecast. It also has a research collaboration agreement with Pfizer Inc. There can be no assurances that the proposed acquisition of AllCell will be completed. and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, which may cause Beam Globals actual results to be materially different from these forward-looking statements. license agreement with Sana Biotechnology, Inc. The company has an alliance with Boston Children's Hospital a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc. It also develops therapies for alpha-1 antitrypsin deficiency ocular diseases and other liver, muscle, and central nervous system disorders. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia BEAM-102 for the treatment of sickle cell disease and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |